GERNNasdaqPharmaceutical PreparationsFiscal year ends December 31

GERON CORP

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026

$1.20+0.03 (+2.56%)

Close on Oct 19, 2026

Market cap: $804.84K
P/E (TTM): –
Dividend yield: –

GERON CORP income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31
Revenue	–	–	0.24	0.60	1.39	0.25	0.46	1.07	1.07	6.16	36	1.15	1.28	2.71	2.44	3.56	1.73
Research & Development	71	104	125	96	86	51	52	13	11	18	18	21	23	51	69	62	58
Selling, General & Admin	159	146	69	44	–	–	–	–	–	–	–	–	–	–	–	–	–
General & Administrative	–	–	69	44	30	26	21	19	19	19	18	17	16	20	24	18	14
Operating Expenses	252	251	194	139	115	77	73	32	30	37	37	37	40	74	99	115	72
Operating Income	-69	-174	-194	-139	-114	-77	-73	-31	-29	-31	-0.56	-36	-39	-72	-96	-111	-70
Interest Expense	33	19	8.31	6.88	3.74	0.76	–	–	–	–	–	–	–	–	–	–	–
Interest & Investment Income	18	20	18	2.53	0.53	1.83	4.22	3.25	–	–	–	–	–	–	–	–	–
Income from Equity Investments	–	–	–	–	–	–	–	–	–	–	–	–	–	–	-0.50	-2.35	-1.34
Other Non-Operating Income	-0.38	-0.24	-0.02	1.00	1.10	0.17	-0.07	-0.11	–	–	–	–	–	–	–	–	–
Merger & Restructuring Charges	17	0	0	–	–	–	–	–	–	–	1.31	–	1.46	2.70	5.45	0	0
Asset Impairment Charges	–	–	–	–	–	–	–	–	–	–	–	–	0.20	0.27	0.87	0	0
Gain (Loss) on Sale of Assets	–	–	–	–	–	–	–	–	-0.01	0.02	–	0.00	0.83	0.14	-0.01	-0.08	-0.13
Legal Settlements	–	–	–	–	–	–	–	1.46	–	–	–	–	–	–	–	–	–
Pretax Income	-83	-175	-182	-142	–	–	–	–	–	–	–	–	–	–	–	–	–
Income Tax Expense	0.08	0.45	0.02	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Net Income incl. Noncontrolling Interests	–	-175	-184	-142	-116	-76	-69	-27	-28	-30	–	–	–	–	–	–	–
Net Income	-84	-175	-184	-142	-116	-76	-69	-27	-28	-30	0.05	-36	-38	-69	-97	-111	-70
EPS (Basic)(per share)	-0.13	-0.27	-0.32	-0.37	-0.35	-0.28	-0.36	-0.15	-0.18	-0.19	0.00	-0.23	-0.30	-0.54	-0.78	-1.14	-0.80
EPS (Diluted)(per share)	-0.13	-0.27	-0.32	-0.37	-0.35	-0.28	-0.36	-0.15	-0.18	-0.19	0.00	-0.23	-0.30	-0.54	-0.78	-1.14	-0.80
Shares Outstanding (Basic, Weighted)(shares)	667	646	571	381	328	271	190	177	159	159	158	154	128	127	125	98	–
Shares Outstanding (Diluted, Weighted)(shares)	667	646	571	381	328	271	190	177	159	159	163	154	128	127	125	98	–
EBITDA	-68	-173	-194	-138	-114	-77	-72	–	–	–	–	–	–	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -33.0%

Financial strength

Current ratio: 6.92
Debt to equity: 0.55
Debt to assets: 23.1%
Cash to current liabilities: 89.1%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 0.00
Dividend yield: –